To Earn CE for this Session: Watch the on-demand recording in its entirety, thenclick here to complete the CE quiz for this session.
Oncology
G. Sylvester Price, DVM, DACVIM (SAIM & Oncology)
Head of Non-Infectious Disease Research
Boehringer Ingelheim
Duluth, Georgia, United States
Christopher Loss, DVM (he/him/his)
Veterinary Medical Officer
FDA / Center for Veterinary Medicine
Alexandria, Virginia, United States
Douglas H. Thamm, VMD, DACVIM (Oncology)
Barbara Cox Anthony Professor of Oncology
Colorado State University
Fort Collins, Colorado, United States
Describe how pharmacologic factors such as a drug’s engagement with its molecular targets, and its in vivo exposure can influence drug efficacy and safety.
Describe the pharmaceutical factors such as drug potency, purity, stability, and impurity characteristics, and the drug’s formulation on its efficacy and safety.
Describe the clinical pathology factors that need to be considered when interpreting results of molecular genetic test conducted on dogs with cancer.